| 000 | 05635cam a2200445Ii 4500 | ||
|---|---|---|---|
| 001 | 96057 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102112736.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 170524s2017 sz a ob 000 0 eng d | ||
| 020 | _a3319536605 | ||
| 020 |
_a3319536613 _q(electronic bk.) |
||
| 020 | _a9783319536606 | ||
| 020 |
_a9783319536613 _q(electronic bk.) |
||
| 020 |
_z9783319536606 _q(print) |
||
| 040 |
_aN$T _cN$T _dEBLCP _dGW5XE _dN$T _dYDX _dOCLCO _dUAB _dESU _dAZU _dUPM _dOCLCF _dOCLCO _dIOG _dOCLCO _dCOO _dMERER _dOCLCO _dVT2 _dOCLCQ _dAUD _dOCLCO _dJG0 _dU3W _dES-MaUEC _bspa |
||
| 050 | 4 |
_aRC268.5 _bM434 2017 EB |
|
| 245 | 0 | 0 |
_aMechanisms of molecular carcinogenesis. _nVolume 2 _cJohannes Haybaeck, editor. |
| 264 | 1 |
_aCham, Switzerland _bSpringer _c2017. |
|
| 264 | 4 | _c2017 | |
| 300 |
_a1 recurso en línea _bilustraciones (algunas a color) |
||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF |
||
| 500 |
_aSpringerLink _bSpringer Biomedical and Life Sciences eBooks 2017 English+International |
||
| 504 | _aIncluye referencias bibliográficas | ||
| 505 | 0 | _aPreface; Contents; 1: Molecular Classification of Breast Cancer; 1.1 Introduction; 1.2 Histopathological Classification of In Situ and Invasive Breast Cancer; 1.2.1 Histological Features of Ductal Carcinoma In Situ; 1.2.2 Histological Types and Grade of Invasive Breast Cancers; 1.3 Molecular Classification of Invasive Breast Carcinoma; 1.3.1 Gene Expression Profiling in Breast Cancer; 1.3.2 Immunohistochemical Surrogates for Intrinsic Subtypes; 1.3.3 Genome Profiling in Breast Cancer; 1.3.4 Special Subtypes; 1.3.5 Familial Breast Cancer. | |
| 505 | 8 | _a1.4 Molecular Classification of Ductal Carcinoma In Situ1.4.1 Molecular Subtypes in DCIS; 1.5 Future Perspectives; References; 2: Nonmelanoma Skin Cancer Actinic Keratosis and Squamous Cell Carcinoma; 2.1 Introduction; 2.2 Histological Classifications; 2.3 Influencing Factors for Carcinogenesis; 2.3.1 UV Radiation; 2.3.2 Inflammation and Cancer; 2.4 Immune Cells in Tumor Genesis; 2.4.1 Innate Immune Cells; 2.4.2 Adaptive Immune Cells; 2.4.3 Tumor Microenvironment; 2.5 Hypoxia or Oxidative Stress and Inflammation; 2.6 Viral Infection; 2.6.1 Acute and Chronic Viral Infection. | |
| 505 | 8 | _a2.6.2 Treatment: Actinic Keratosis2.7 Targeted Therapies in AK; 2.7.1 5 Fluorouracil (5-FU); 2.7.2 Imiquimod; 2.7.3 Cyclooxygenase (COX)-2 Inhibitors; 2.7.4 Ingenol Mebutate; 2.7.5 Photodynamic Therapy (PDT); 2.7.6 Treatment: Cutaneous Squamous Cell Cancer; 2.8 Future (Targeted) Therapies or Treatment Options Used in Clinical Studies; 2.8.1 Anti-epidermal Growth Factor Receptors (EGFR); References; 3: Molecular Pathogenesis of Bone Tumours; 3.1 Introduction; 3.2 Tumour Types; 3.2.1 Cartilage Tumours; 3.2.2 Osteogenic Tumours; 3.2.3 Ewing Sarcoma; 3.2.4 Haematopoietic Tumours. | |
| 505 | 8 | _a3.2.5 Giant Cell Tumours3.2.6 Notochordal Tumours (Chordoma); 3.2.7 Tumours of Undefined Neoplastic Nature; 3.2.7.1 Aneurysmal Bone Cysts; 3.2.7.2 Simple Bone Cyst; 3.2.7.3 Fibrous Dysplasia; 3.2.7.4 Osteofibrous Dysplasia; 3.2.7.5 Langerhans Cell Histiocytosis; 3.2.7.6 Erdheim-Chester Disease; 3.2.7.7 Chest Wall Hamartoma; 3.3 Molecular Pathogenesis; 3.3.1 AEG-1; 3.3.2 ATRX; 3.3.3 CDKN2A; 3.3.4 CTGF; 3.3.5 ET-1; 3.3.6 EXT1; 3.3.7 GNAS; 3.3.8 IDH1; 3.3.9 MDM2; 3.3.10 MEF2D; 3.3.11 MET; 3.3.12 NKD2; 3.3.13 PRIM1; 3.3.14 RUNX Family; 3.3.14.1 RUNX2; 3.3.14.2 RUNX3. | |
| 505 | 8 | _a3.3.15 SATB23.3.16 TP53; 3.3.17 WIF-1; 3.4 Syndromes; 3.4.1 Li-Fraumeni Syndrome; 3.4.2 Mazabraud Syndrome; 3.4.3 McCune-Albright Syndrome; 3.4.4 Ollier Disease (Enchondromatosis); 3.4.5 Paget's Disease of Bone; 3.4.6 Retinoblastoma; 3.4.7 Rothmund-Thomson Syndrome; 3.4.8 Werner Syndrome; References; 4: Molecular and Cellular Mechanisms of Carcinogenesis in the Large Bowel; 4.1 Introduction; 4.2 Molecular Classification of Colorectal Cancer; 4.2.1 The Chromosomal Instability (CIN) Pathway; 4.2.2 Microsatellite Instability (MSI) Pathway and Lynch Syndrome (LS). | |
| 520 | 3 | _aTogether with Volume 1, this book provides an inclusive overview of the molecular and cellular mechanisms of carcinogenesis and offers comprehensive insights into related clinical and therapeutic aspects. This second volume complements the first by presenting and concisely explaining the carcinogenesis of various tumor entities such as non-melanoma skin cancers, bone and soft tissue tumors, pancreatic cancers, hepatocellular cancer and neuroendocrine tumors. As in volume one, each chapter illuminates the similarities and dissimilarities of changed signaling pathways in the different organ systems and depicts potential therapeutic strategies. The focus of volume two lies on the presentation of modern molecular biological techniques for diagnosis, as well as strategies for biomarker identification and validation. Furthermore, it discusses potential therapeutic targets and individualized treatment strategies, offering a valuable resource for all basic scientists and medical researchers interested in translational cancer research. | |
| 650 | 7 |
_aCarcinogénesis _xMolecular aspects. _2embne _0(OCoLC)fst00846978 _0comprobar BNE19923478372 _9146492 |
|
| 700 | 1 |
_aHaybaeck, Johannes, _eeditor literario |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-53661-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 988 | _aEBOOK, asignarmaterias, EBSPRINGER_2017D | ||
| 998 |
_b02/2018 _dz _e- _zSI |
||
| 999 |
_c96057 _d96057 _x1 |
||